These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 27846573)
1. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Pelczar P; Witkowski M; Perez LG; Kempski J; Hammel AG; Brockmann L; Kleinschmidt D; Wende S; Haueis C; Bedke T; Witkowski M; Krasemann S; Steurer S; Booth CJ; Busch P; König A; Rauch U; Benten D; Izbicki JR; Rösch T; Lohse AW; Strowig T; Gagliani N; Flavell RA; Huber S Science; 2016 Oct; 354(6310):358-362. PubMed ID: 27846573 [TBL] [Abstract][Full Text] [Related]
2. miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD. He C; Shi Y; Wu R; Sun M; Fang L; Wu W; Liu C; Tang M; Li Z; Wang P; Cong Y; Liu Z Gut; 2016 Dec; 65(12):1938-1950. PubMed ID: 26338824 [TBL] [Abstract][Full Text] [Related]
3. Lnc-ITSN1-2, Derived From RNA Sequencing, Correlates With Increased Disease Risk, Activity and Promotes CD4 Nie J; Zhao Q Front Immunol; 2020; 11():852. PubMed ID: 32547537 [No Abstract] [Full Text] [Related]
5. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. Iijima H; Takahashi I; Kishi D; Kim JK; Kawano S; Hori M; Kiyono H J Exp Med; 1999 Sep; 190(5):607-15. PubMed ID: 10477546 [TBL] [Abstract][Full Text] [Related]
6. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899 [TBL] [Abstract][Full Text] [Related]
7. Role of miR-22 in intestinal mucosa tissues and peripheral blood CD4+ T cells of inflammatory bowel disease. Pei XF; Cao LL; Huang F; Qiao X; Yu J; Ye H; Xi CL; Zhou QC; Zhang GF; Gong ZL Pathol Res Pract; 2018 Aug; 214(8):1095-1104. PubMed ID: 29880327 [TBL] [Abstract][Full Text] [Related]
9. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. Pedersen G Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335 [TBL] [Abstract][Full Text] [Related]
10. In vitro activated CD4+ T cells from interferon-gamma (IFN-gamma)-deficient mice induce intestinal inflammation in immunodeficient hosts. Bregenholt S; Brimnes J; Nissen MH; Claesson MH Clin Exp Immunol; 1999 Nov; 118(2):228-34. PubMed ID: 10540183 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Globig AM; Hennecke N; Martin B; Seidl M; Ruf G; Hasselblatt P; Thimme R; Bengsch B Inflamm Bowel Dis; 2014 Dec; 20(12):2321-9. PubMed ID: 25248005 [TBL] [Abstract][Full Text] [Related]
13. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196 [TBL] [Abstract][Full Text] [Related]
14. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease. Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464 [TBL] [Abstract][Full Text] [Related]
15. Alterations of the mucosal immune system in inflammatory bowel disease. MacDermott RP J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661 [TBL] [Abstract][Full Text] [Related]
16. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Huber S; Gagliani N; Zenewicz LA; Huber FJ; Bosurgi L; Hu B; Hedl M; Zhang W; O'Connor W; Murphy AJ; Valenzuela DM; Yancopoulos GD; Booth CJ; Cho JH; Ouyang W; Abraham C; Flavell RA Nature; 2012 Nov; 491(7423):259-63. PubMed ID: 23075849 [TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Sarra M; Monteleone I; Stolfi C; Fantini MC; Sileri P; Sica G; Tersigni R; Macdonald TT; Pallone F; Monteleone G Inflamm Bowel Dis; 2010 Aug; 16(8):1332-9. PubMed ID: 20186935 [TBL] [Abstract][Full Text] [Related]
18. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality? van Hogezand RA; Verspaget HW Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802 [TBL] [Abstract][Full Text] [Related]
19. New targets for mucosal healing and therapy in inflammatory bowel diseases. Neurath MF Mucosal Immunol; 2014 Jan; 7(1):6-19. PubMed ID: 24084775 [TBL] [Abstract][Full Text] [Related]
20. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. Ten Hove T; The Olle F; Berkhout M; Bruggeman JP; Vyth-Dreese FA; Slors JF; Van Deventer SJ; Te Velde AA J Leukoc Biol; 2004 Jun; 75(6):1010-5. PubMed ID: 15020649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]